Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01251380 · ClinicalTrials.gov registry record · Phase 3

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

A Phase 3 study, sponsored by Ipsen.

Completed
Registry status
Phase 3
Development phase
216
Enrollment target

NCT01251380 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 216 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01251380, a Phase 3 study, has completed, sponsored by Ipsen.

COMPLETED
Registry status
Phase 3
Development phase
216 participants
Enrollment target

Study Summary

The purpose of this research study was to determine the long term safety and efficacy of repeated treatments with Dysport® used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy.

Interventions

  • BIOLOGICAL Botulinum toxin type A

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2011-10
Est. Completion 2015-01
Phase Phase 3

Sponsor

Ipsen

85 total trials

What the Registry Record Tells You About NCT01251380

The ClinicalTrials.gov registry entry for NCT01251380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.

NCT01251380 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01251380 about?

NCT01251380 is a clinical study titled "Dysport® Pediatric Lower Limb Spasticity Follow-on Study". The purpose of this research study was to determine the long term safety and efficacy of repeated treatments with Dysport® used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy.

What is the current status of trial NCT01251380?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2011-10. Estimated completion is 2015-01.

What interventions are being tested in trial NCT01251380?

The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).

Who is sponsoring clinical trial NCT01251380?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.